Organization | Prostate Cancer Foundation of Australia

Prostate Cancer Foundation of Australia Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial

2018

NCT03392428

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Prostate Cancer Foundation of Australia | Prostate Cancer Foundation of Australia (PCFA)

Active Ingredients

Drugs in Phase 2 Trials (4)

cabazitaxel (jevtana kit) (1 trial)

ipilimumab (yervoy) (1 trial)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (2 trials)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Prostatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 4